•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student
other

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences

Amarchand, HSB, K&L Gates on US Par Pharma acquisition of Chennai ‘bioavailability, bioequivalence, pharmacokinetic’ labs

Amarchand Mangaldas and K&L Gates advised US-based Par Pharmaceuticals and its wholly-owned Indian subsidiary Par Formulations on its acquisition of Chennai-based Ethics Biolabs, which was advised by HSB Partners.

Amarchand Delhi partners Amit Kumar and Arvind Sharma, principal associate designate Janani Sekhar and senior associate Ananda Malhotra acted for Par Pharmaceuticals.

HSB partners TK Bhaskar and Varun Sriram with associate Anantha Krishnan Iyer acted for Ethics Biolabs and its selling promoters. Ethics conducts “bioavailability, bioequivalence, pharmacokinetic and clinical end point studies for pharmaceutical and biotechnology companies”, started an Amarchand press release. The value of the deal, which closed on 14 January, was confidential.

No comments yet: share your views

Latest comments